Intensity Therapeutics Inc. (NASDAQ:INTS) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Intensity Therapeutics Inc. (NASDAQ:INTS) have earned an average recommendation of “Moderate Buy” from the five research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $7.00.

Several equities analysts have commented on INTS shares. HC Wainwright raised their price target on shares of Intensity Therapeutics from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Tuesday, August 18th. Citigroup reaffirmed a “buy” rating on shares of Intensity Therapeutics in a research report on Tuesday, August 11th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Intensity Therapeutics in a research report on Tuesday, July 21st.

Intensity Therapeutics Stock Performance

Shares of INTS opened at $3.42 on Wednesday. The stock’s 50-day simple moving average is $4.17 and its 200 day simple moving average is $4.66. Intensity Therapeutics has a 52-week low of $3.27 and a 52-week high of $43.50. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.00 and a current ratio of 5.00. The stock has a market capitalization of $11.15 million, a price-to-earnings ratio of -0.96 and a beta of 2.76.

Intensity Therapeutics (NASDAQ:INTS) last released its earnings results on Tuesday, August 11th. The company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.24). Research analysts forecast that Intensity Therapeutics will post -2.64 EPS for the current fiscal year.

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to treat solid tumors and stimulate the body’s immune system. The company’s approach is based on its proprietary DfuseRx technology, which is intended to improve the delivery of anticancer agents into tumor cells while promoting an immune response against treated and potentially untreated tumors.

Its lead product candidate, INT230-6, is an investigational intratumoral therapy that combines the cancer-killing agents cisplatin and vinblastine with a formulation designed to facilitate their distribution within tumors.